Recevez les dernières nouvelles sur l'action Intellia Therapeutics avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de NTLA

Dernières nouvelles pour

INTELLIA THERAPEUTICS INC

Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Press Releases

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

News

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Legal

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Earnings

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Health Care

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Small Cap

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

NTLA

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Immunome

Immatics

Janux Therapeutics

MannKind

NuCana

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Stoke Therapeutics

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Vericel

Zenas BioPharma

Zymeworks

Wells Fargo

JMP Securities

Barclays

RBC Capital

Bernstein

Comments

Intellia Therapeutics Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL